Flotillin‐1/2 Autoimmunity in a Patient with Marginal Zone Lymphoma

The flotillin-1/2 heterocomplex seems to be a potential autoantigen in a subset of about 1–2% multiple sclerosis (MS) patients. Rarely humoral central nervous system (CNS) autoimmunity against neural surface associated proteins has yet been linked to underlying latent hematologic malignancies. Herein, we demonstrate a case of inflammatory CNS disease with flotillin auto-antibodies in the context of a marginal zone lymphoma. ES was supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) within the framework of the Munich Cluster for Systems Neurology (EXC 1010 SyNergy). LK is an employee of Euroimmun AG, which manufactures and markets assay kits for detecting flotillin antibodies. RFeuerecker, RForstpointner and AS report no disclosures relevant to the manuscript. TK reports no disclosures relevant to the manuscript, but has received travel expenses and speaker honoraria from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, CLS Behring, Roche Pharma and Biogen, as well as grant support from Bayer-Schering AG, Novartis and Chugai Pharma. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.